Stock Under $10 with 50-100% upside potential - 14 Days FREE!

4 Biotech Stocks Under $10 Soaring Higher

Stock quotes in this article: ARRY, BPAX, SVA, GENE 

Sinovac Biotech

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Sinovac Biotech (SVA) is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against infectious diseases. This stock is trading up 9.4% at $2.72 in recent trading.

Today's Range: $2.55-$2.82

52-Week Range: $1.64-$2.88

Volume: 225,000

Three-Month Average Volume: 61,992

>>8 Stocks Ripping Higher on Big Volume

From a technical perspective, SVA is gapping up sharply here with above-average volume, and it's starting to break out above some near-term overhead resistance levels at $2.64 to $2.75.

Traders should now watch for the next major breakout trade to trigger for SVA. That trade will hit once SVA manages to clear some past overhead resistance at $2.88 with high volume. You can look for long-biased trades in SVA as long as it's trending above today's low of $2.56, and then once it sustains a move or close above $2.88 with volume that's near or above 61,992 shares. If that breakout triggers soon, then SVA will setup to re-test or possibly take out its next major overhead resistance at $3.33.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,267.42 -27.08 -0.18%
NASDAQ 3,446.45 -12.97 -0.37%
S&P 500 1,643.79 -6.72 -0.41%
US 10 Yr 2.005% -0.018

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs